China Healthcare Select

IMPACT Therapeutics, Inc., a Nanjing-based biotech founded in 2009 and specializing in synthetic lethality, has filed for an IPO on the Hong Kong Stock Exchange. The company’s lead product, Senaparib (a PARP1/2 inhibitor), was approved in China in January 2025 for first-line maintenance treatment of ovarian cancer in all patients regardless of BRCA status. Its pipeline includes 13 assets: 1 commercialized, 4 in clinical stages, and 7 preclinical candidates targeting key synthetic lethality pathways such as PARP1-selective, ATR, WEE1, PKMYT1, DHX9, ATM, USP1, CHK1/2, PROTACs, and CEACAM5 ADCs. Despite generating RMB 38.3M in 2025 revenue—more than half from drug sales—the company reported a net loss of RMB 295.9M and carries a RMB 980.2M redemption liability that would convert to equity upon successful IPO completion. Key investors include Tencent, WuXi AppTec, LAV, and Decheng Capital.

Weimai Inc., an AI-driven healthcare digital platform, has filed its prospectus for a Hong Kong IPO. The company reported FY2025 revenue of RMB 863.4 million, up 32.3% YoY, driven by rapid growth in CareAI/AI Services (+44.6%) and the launch of a high-margin Dedicated IP Licensing segment (32.8% gross margin). Despite achieving positive Adjusted EBITDA of RMB 1.4 million for the first time, Weimai posted a net loss of RMB 290.1 million, largely due to soaring share-based compensation expenses (RMB 237.8 million). With 188 CareAI deployments and 4,800 API integrations, the company holds ~4% market share in China’s fast-growing AI healthcare sector, which is projected to expand at a 32.7% CAGR through 2030.

Weimai Inc., an AI-driven healthcare digital solutions platform, has filed for a Hong Kong Stock Exchange listing. The company reported FY2025 revenue of RMB 863.4M, up 32.3% YoY, with gross margin improving to 21.7%. Despite a net loss of RMB 290.1M—widened primarily due to RMB 237.8M in non-cash charges—its adjusted EBITDA turned positive at RMB 1.4M. Weimai operates a B2B2C ecosystem featuring CareAI (188 hospital deployments), Medical AI Solutions (M.A.S), an API ecosystem (4,800 integrations), and proprietary IP licensing (70 assets). It holds a 5.2% market share in China’s CareAI segment within a rapidly growing AI healthcare market projected to expand at a 32.7% CAGR through 2030. However, R&D spending remains below peer averages at 8.3% of revenue, raising questions about the sustainability of its AI differentiation.

Preliminary statistics from VCBeat tracked 10 financing events in China's healthcare sector between April 13 and 17, 2026 (excluding IPOs and private placements). The period was led by Polyncure's Seed Round in the tens of millions of RMB, followed by Fusu Life Science and Technology's Angel Round of RMB 20 million.

METiS TechBio Co., Ltd., a pre-commercial AI-driven nanomedicine company founded in 2020, has filed for an IPO on the Hong Kong Stock Exchange under Chapter 18C. The company leverages its NanoForge platform—powered by a proprietary lipid library of over 10 million structures—and four core AI platforms (AiTEM, AiLNP, AiRNA, and NanoForge) to accelerate drug delivery innovation. Its lead program, MTS-004, entered Phase III trials following a RMB 100 million out-licensing deal in September 2025, driving 2025 revenue to RMB 105 million from just RMB 1.5 million in 2024. Despite narrowing net losses to RMB 391.8 million in 2025 and holding RMB 828.3 million in cash, METiS reports accumulated losses of RMB 1.75 billion and high customer concentration risk. The IPO proceeds will support AI platform enhancement, clinical advancement of MTS-201/105/109, non-hepatic LNP validation, global partnerships, and animal health initiatives.

However, these synergistic integration efforts have not reached the ideal state. Trividia and PTS have often experienced performance losses and goodwill impairment, affecting Sinocare's profits. For example, in 2019, the business operations of PTS were impacted, resulting in goodwill impairment of 25 to 50 million RMB; Trividia's operating loss impacted Sinocare's investment income by approximately -60 to -75 million RMB. In 2020, both PTS and Trividia were in a state of operating loss. In 2021, Trividia continued to incur losses; in 2023, Trividia faced operating losses and goodwill impairment.